HERMES-24评分在大血管闭塞治疗后的简单稳健结局预测中的推导与验证
研究利用HERMES协作数据集(n=1764)及ESCAPE-NA1(n=1066)和INTERRSeCT(n=614)外部验证队列,在血管内取栓治疗和后循环对照患者中推导并验证了治疗后24小时HERMES-24评分(年龄/10+24小时NIHSS评分)。该评分对90天mRS≤2显示出高预测能力(推导队列c统计量0.907,验证队列0.914,对照臂0.909),评分≥25时mRS≤2的观察概率为3.1%-3.4%,评分<10时为90.6%-93.0%。
要点
- HERMES-24评分=年龄(岁)/10+24小时NIHSS评分,简单易算。
- 推导队列c统计量0.907(95%CI 0.879-0.935),验证队列0.914(95%CI 0.886-0.944)。
- 评分≥25时mRS≤2概率仅3.1%-3.4%,评分<10时高达90.6%-93.0%。
关键数值与推荐
- HERMES-24评分计算公式:年龄(岁)/10+24小时NIHSS评分。
- 推导队列中mRS≤2的c统计量为0.907(95%CI 0.879-0.935)。
- 验证队列中mRS≤2的c统计量为0.914(95%CI 0.886-0.944),对照臂为0.909(95%CI 0.887-0.930)。
- 评分≥25时mRS≤2的观察概率为3.1%-3.4%,评分<10时为90.6%-93.0%。
- ESCAPE-NA1和INTERRSeCT人群中mRS≤2的c统计量分别为0.894和0.889。
临床怎么用
- 作者认为HERMES-24评分可用于前循环大血管闭塞卒中治疗后第2天与家属进行预后讨论。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinicians need simple and highly predictive prognostic scores to assist practical decision-making. We aimed to develop a simple outcome prediction score applied 24 hours after anterior circulation acute ischemic stroke treatment with endovascular thrombectomy and validate it in patients treated both with and without endovascular thrombectomy. METHODS: Using the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration data set (n=1764), patients in the endovascular thrombectomy arm were divided randomly into a derivation cohort (n=430) and a validation cohort (n=441). From a set of candidate predictors, logistic regression modeling using forward variable selection was used to select a model that was both parsimonious and highly predictive for modified Rankin Scale (mRS) ≤2 at 90 days. The score was validated in validation cohort, control arm (n=893), and external validation cohorts from the ESCAPE-NA1 (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischaemic Stroke; n=1066) and INTERRSeCT (Identifying New Approaches to Optimize Thrombus Characterization for Predicting Early Recanalization and Reperfusion With IV Alteplase and Other Treatments Using Serial CT Angiography; n=614). RESULTS: In the derivation cohort, we selected 2 significant predictors of mRS ≤2 (National Institutes of Health Stroke Scale score at 24 hours and age [β-coefficient, 0.34 and 0.06]) and derived the HERMES-24 score: age (years)/10+National Institutes of Health Stroke Scale score at 24 hours. The HERMES-24 score was highly predictive for mRS ≤2 (c-statistic 0.907 [95% CI, 0.879-0.935]) in the derivation cohort. In the validation cohort and the control arm, the HERMES-24 score predicts mRS ≤2 (c-statistic, 0.914 [95% CI, 0.886-0.944] and 0.909 [95% CI, 0.887-0.930]). Observed provability of mRS ≤2 ranged between 3.1% and 3.4% when HERMES-24 score ≥25, while it ranged between 90.6% and 93.0% when HERMES-24 score <10 in the derivation cohort, validation cohort, and control arm. The HERMES-24 score also showed c-statistics of 0.894 and 0.889 for mRS ≤2 in the ESCAPE-NA1 and INTERRSeCT populations. CONCLUSIONS: The post-treatment HERMES-24 score is a simple validated score that predicts a 3-month outcome after anterior circulation large vessel occlusion stroke regardless of intervention, which helps prognostic discussion with families on day 2.
引用
- Tanaka K, Brown S, Goyal M, et al. HERMES-24 Score Derivation and Validation for Simple and Robust Outcome Prediction After Large Vessel Occlusion Treatment. Stroke. 2024. PMID: 39038101. doi:10.1161/STROKEAHA.123.045871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。